Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Dublin, Jan. 04, 2017 -- Research and Markets has announced the addition of the "Endometriosis - Global Strategic Business Report" report to their offering.
This report analyzes the worldwide markets for Endometriosis in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World.
Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research.
The report profiles 38 companies including many key and niche players such as
- AbbVie Inc. (US)
- AEterna Zentaris Inc. (Canada)
- Astellas Pharma Inc. (Japan)
- AstraZeneca Plc. (UK)
- Bayer HealthCare Pharmaceuticals, Inc. (US)
- Debiopharm Group (Switzerland)
- Evotec AG (Germany)
- Kissei Pharmaceutical Co., Ltd. (Japan)
- Neurocrine Biosciences, Inc. (US)
- ObsEva SA (Switzerland)
- Pfizer, Inc. (US)
- Repros Therapeutics, Inc. (US)
- Roivant Sciences Ltd. (US)
- Takeda Pharmaceutical Company Limited (Japan)
- ValiRx Plc (UK)
Key Topics Covered:
1. Industry Overview
2. Endometriosis & Its Treatment - An Overview
3. Treatment Of Endometriosis
4. Select Clinical Trials/Product Innovations & Approvals
5. Recent Industry Activity
6. Focus On Select Global Players
7. Global Market Perspective
Total Companies Profiled: 38 (including Divisions/Subsidiaries 40)
- The United States (11)
- Canada (3)
- Japan (6)
- Europe (15)
- - France (1)
- - Germany (3)
- - The United Kingdom (2)
- - Rest of Europe (9)
- Asia-Pacific (Excluding Japan) (4)
- Middle-East (1)
For more information about this report visit http://www.researchandmarkets.com/research/qwzt5g/endometriosis
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Women's Health
